Kheiron

What Kheiron does

Kheiron Medical Technologies was a London-based medical-AI company founded in 2016 that built Mia™ (Mammography Intelligent Assessment), a deep-learning clinical decision support tool for breast cancer screening. Mia analyzed mammogram images to flag lesions potentially missed by human review and could be deployed as an independent reader, concurrent reader, or triage tool. The product received CE marking in Europe in 2019 and was validated in a real-world NHS Grampian study of more than 10,000 women, which reported a 10.4% improvement in cancer detection, a 30%+ reduction in radiologist workload, and a reduction in patient notification time from 14 days to 3 days. The underlying technology relies on proprietary computer vision and anomaly detection models trained on mammography data, with published results in Nature Cancer supporting the evidence base.

Kheiron monetized through subscription and enterprise licensing to healthcare institutions, NHS trusts, and oncology screening programs. Its go-to-market was direct enterprise field sales into radiology and IT departments, supplemented by research partnerships with academic centers (University of Aberdeen) and clinical-trial consortia (EDITH) to build the peer-reviewed evidence base that healthcare buyers require. The company won the NHS AI in Health and Care Award in 2020 and raised approximately $22 million in a 2019 Series A led by Atomico, with prior seed rounds from Greycroft, Connect Ventures, Acequia Capital, and others.

In 2024, Kheiron was acquired by DeepHealth, a wholly-owned subsidiary of RadNet Inc. (NASDAQ: RDNT), for a disclosed $1 million. Mia's capabilities have been integrated into DeepHealth's SmartMammo™ product within the broader Population Health portfolio (which also covers prostate, lung, brain, and thyroid diagnostics). Through RadNet's network of 399 imaging centers across 8 US states and continued UK NHS engagement, the technology now has a distribution footprint that would have been inaccessible as a standalone startup. Kheiron's prior revenue is not publicly disclosed; the low acquisition price implies the standalone business had not achieved material commercial scale before being absorbed.

Name

Kheiron

Legal name

Kheiron Medical Technologies Limited

Website

https://kheironmed.com

Company type

Private

Founded year

2016

Operating status

Acquired

Headcount range

11–50 employees

Short description

Kheiron Medical Technologies developed Mia™, an AI-powered mammography analysis tool that assists radiologists in breast cancer screening. Founded in London in 2016, the company was acquired by DeepHealth (RadNet subsidiary) in 2024 and integrated into SmartMammo™.

Ownership category

akta.pro rank

Product category

AI Medical Imaging Software

NAICS

Diagnostic Imaging Centers (621512), Medical and Diagnostic Laboratories (62151), Irradiation Apparatus Manufacturing (334517)

SIC

X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Mammography & Breast Imaging Systems (HLAHABAF)

akta.pro secondary industries

AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG), Teleradiology Platforms & Reading Workflow (HLACALAK), Universal Viewers & Enterprise Imaging Access (Zero-footprint/Diagnostic) (HLACALAD), Quality, Peer Review & Compliance Tools (MQSA/ACR/QA) (HLACALAL), Vendor Neutral Archive (VNA) & Enterprise Imaging Repositories (HLACALAC), Radiology Reporting, Dictation & Structured Reporting (HLACALAF), Imaging Interoperability & Standards Enablement (DICOM/HL7/FHIR/IHE) (HLACALAJ)

Keywords

• AI breast cancer detection
• Mammography screening software
• Radiology decision support
• Medical imaging AI
• Diagnostic workflow software

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. AI Medical Software Licensing: Licensing of AI-powered medical software solutions (Mia) to healthcare institutions for clinical use in breast cancer screening. Revenue generated through software licensing agreements with hospitals, imaging centers, and healthcare systems.
2. Healthcare Enterprise Sales: Enterprise contracts with healthcare providers and NHS institutions for AI diagnostic solutions, deployed in clinical workflows.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Kheiron Medical Technologies develops and sells Mia™ (Mammography Intelligent Assessment), an AI-powered software solution that analyzes mammogram images to flag areas suspicious for breast cancer and supports radiologists in screening decisions. Mia operates as an independent reader, concurrent reader, or triage tool, and is licensed to healthcare institutions, NHS trusts, and oncology centers for use in breast cancer screening programs. Following the 2024 acquisition by DeepHealth (a RadNet subsidiary), Mia's capabilities now anchor the SmartMammo / Breast Suite product line.

Product overview

Kheiron Medical Technologies, now part of DeepHealth (a RadNet subsidiary), developed AI-powered solutions for cancer diagnostics with a primary focus on breast cancer screening. The company's core product was Mia (Mammography Intelligent Assessment), an AI system that supports radiologists in detecting breast cancer from mammogram images. Mia functioned as an independent reader, concurrent reader, or triage tool. In 2024, Kheiron was acquired by DeepHealth and Mia's capabilities were integrated into DeepHealth's SmartMammo/ Breast Suite product within the Population Health portfolio, which also includes solutions for prostate, lung, brain, and thyroid diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

• Mia™ (Mammography Intelligent Assessment): AI-powered solution for breast cancer screening that supports radiologists in decision-making, used as an independent reader, concurrent reader, and triage tool.

Products and services

• Mia™ (Mammography Intelligent Assessment) AI-powered mammography assessment software that analyzes mammogram images and flags areas suspicious for breast cancer. Supports radiologists in breast screening decision-making and can be deployed as an independent reader, concurrent reader, or triage tool for healthcare institutions and screening programs.

Quantifiable outcome

• 10.4% improvement in breast cancer detection rate
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Partnerships

Three partnerships are on record, tiered core and flagship.

• University of AberdeencoreStrategic or Co-development Partner · 1 January 2024Research collaboration led by University of Aberdeen evaluating Mia AI software in NHS Grampian breast cancer screening program. Study published findings in Nature Cancer journal showing 10.4% improvement in cancer detection across 10,000+ women.
• NHS GrampiancoreStrategic or Co-development PartnerClinical partnership for real-world evaluation of AI breast cancer screening technology. NHS Grampian implemented Mia in routine breast screenings, demonstrating workflow improvements and detection accuracy gains.
• EDITH Trial ConsortiumflagshipStrategic or Co-development PartnerMulti-site UK trial expanding AI breast screening evaluation. Mia findings from NHS Grampian will inform EDITH trial deployment across multiple UK sites for broader clinical validation.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Hologic: Major incumbent in women's health and mammography equipment with Genius AI detection software. Broadly comparable as a dominant player in the breast imaging space with both hardware and AI software offerings.
• Siemens Healthineers: Major imaging equipment vendor with AI-enabled mammography offerings and broader radiology IT portfolio. Comparable as a broad incumbent competing in AI-enhanced breast screening deployments.
• GE HealthCare: Global medical imaging incumbent offering mammography systems and broader AI imaging analytics. Comparable as a large-scale incumbent in diagnostic imaging that competes for AI mammography contracts at healthcare systems.

Direct peers

• Lunit: Korean medical AI company with leading breast cancer detection product (Lunit INSIGHT MMG). Directly comparable as an AI mammography vendor serving global radiology markets with FDA-cleared and CE-marked products.
• Therapixel: French AI company whose MammoScreen product is CE-marked for mammography triage — directly comparable to Kheiron's Mia in clinical function, regulatory pathway, and European market positioning.
• ScreenPoint Medical: Dutch AI company developing Transpara breast imaging software for mammography reading support. Directly comparable as a CE-marked AI mammography vendor competing for the same European and global breast screening customers.
• iCAD: AI-powered breast health solutions company that directly competes with Kheiron's Mia in mammography AI. Now being acquired by RadNet (Kheiron's parent), creating an internal portfolio overlap. Highly relevant given identical product category and now-shared ownership.

Others

• DeepHealth: Kheiron's parent company and AI-powered health informatics subsidiary of RadNet. Relevant as the operating platform that now commercializes Mia as SmartMammo across RadNet's US imaging network.
• RadNet: Acquirer of Kheiron and operator of 399 US imaging centers. Relevant as both the distribution channel for Mia/SmartMammo and the broader strategic owner whose portfolio decisions shape Kheiron's commercial trajectory.

Emerging players

• Volpara Health Technologies: Breast imaging analytics platform providing AI-driven patient risk assessment and reporting. Comparable as an AI software layer serving breast screening programs, though more focused on risk/quality analytics than primary cancer detection.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/kheironmedical
• Facebookfacebook.com/1124746784313549

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds10 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kheiron